am 251 has been researched along with Pain in 44 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization." | 7.78 | Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. ( Keresztes, A; Largent-Milnes, TM; Ren, J; Roeske, WR; Tumati, S; Vanderah, TW; Varga, EV, 2012) |
| "N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents." | 5.34 | New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007) |
| "It is aimed to investigate the possible contribution of cannabinoid system that supresses the nociceptive process by the activation of CB1 and CB2 receptors in central and peripheral levels of pain pathways, to the analgesic activity of protocatechuic acid." | 3.91 | Cannabinoid system involves in the analgesic effect of protocatechuic acid. ( Arslan, R; Bektas, N; Dikmen, DY; Okcay, Y, 2019) |
| "Chemical stimulation of the lateral hypothalamus (LH) with carbachol induces antinociception which is antagonized by blockade of orexin receptors in some pain modulatory sites in the tail-flick test." | 3.83 | Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats. ( Esmaeili, MH; Ezzatpanah, S; Haghparast, A; Reisi, Z, 2016) |
| "The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis (OA) but has failed in clinical trials." | 3.81 | A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis. ( Binkowski, M; Czaja, M; Di Marzo, V; Kolosowska, N; Makuch, W; Malek, N; Morera, E; Mrugala, M; Przewlocka, B; Starowicz, K, 2015) |
| "Spinal glial activation has been implicated in sustained morphine-mediated paradoxical pain sensitization." | 3.78 | Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. ( Keresztes, A; Largent-Milnes, TM; Ren, J; Roeske, WR; Tumati, S; Vanderah, TW; Varga, EV, 2012) |
| "In this study we analyzed the mechanisms underlying celecoxib-induced analgesia in a model of inflammatory pain in rats, using the intracerebroventricular (i." | 3.78 | Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system. ( Bakhle, YS; Camêlo, VM; Dos Reis, WG; Faraco, A; Francischi, JN; Paiva-Lima, P; Rezende, RM, 2012) |
| "Neurotensin modulates pain via its actions within descending analgesic pathways which include brain regions such as the midbrain periaqueductal grey (PAG)." | 3.75 | Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey. ( Kawahara, H; Mitchell, VA; Vaughan, CW, 2009) |
| "This study shows that electroacupuncture increases the anandamide level in inflammatory skin tissues, and CB2 receptors contribute to the analgesic effect of electroacupuncture in a rat model of inflammatory pain." | 3.75 | Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats. ( Chen, L; Li, F; Li, M; Li, YH; Pan, HL; Qiu, Y; Shi, J; Wang, L; Zhang, J, 2009) |
| "Cannabinoids, such as anandamide, are involved in pain transmission." | 3.74 | AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain. ( Bianchi, R; Borsani, E; Labanca, M; Rodella, LF, 2007) |
| "Stress contributes to major depressive disorder (MDD) and chronic pain, which affect a significant portion of the global population, but researchers have not clearly determined how these conditions are initiated or amplified by stress." | 1.62 | mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress. ( Han, J; Huang, M; Luo, L; Ma, X; Shi, H; Su, C; Wang, A; Wang, H; Wang, W; Wu, K; Xu, T; Xu, X; Yuan, T, 2021) |
| "Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients." | 1.56 | Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020) |
| "Pain was induced by formalin (2%) injection into the hind paw." | 1.42 | Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors. ( Ali Reza, M; Azizi, H; Mirnajafi-Zadeh, J; Mohammad-Pour Kargar, H; Semnanian, S, 2015) |
| "Substance P release was measured as neurokinin 1 (NK1) receptor internalization in lamina I neurons." | 1.36 | Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization. ( Chen, W; Lao, L; Marvizón, JC; Zhang, G, 2010) |
| "Cholestasis is associated with increased activity of the endogenous opioid system that results in analgesia." | 1.35 | The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis. ( Hasanein, P, 2009) |
| "N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents." | 1.34 | New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007) |
| "Mechanical allodynia and thermal hyperalgesia were evaluated in 46 rats allocated to receive: (1) Vehicle (before surgery)-Vehicle (after surgery); (2) Vehicle-WIN55,212-2; (3) WIN55,212-2-Vehicle; (4) WIN55,212-2-WIN55,212-2; (5) AM251+vehicle; (6) AM251+WIN55,212-2; (7) AM630+vehicle; (8) AM630+WIN55,212-2; (9) Sham receiving vehicle; and (10) Sham receiving WIN55,212-2." | 1.34 | Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. ( Beaulieu, P; Dani, M; Desroches, J; Guindon, J, 2007) |
| " The dose-response curve of i." | 1.32 | Topical cannabinoid antinociception: synergy with spinal sites. ( Akar, A; Bilgin, F; Dogrul, A; Gul, H; Guzeldemir, E; Yildiz, O, 2003) |
| "Anandamide was able to inhibit dural blood vessel dilation brought about by electrical stimulation by 50%, calcitonin gene-related peptide (CGRP) by 30%, capsaicin by 45%, and nitric oxide by 40%." | 1.32 | Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. ( Akerman, S; Goadsby, PJ; Kaube, H, 2004) |
| "WIN 55,212-2 attenuated both heat and mechanical hyperalgesia dose-dependently." | 1.32 | Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. ( Johanek, LM; Simone, DA, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 23 (52.27) | 24.3611 |
| 2020's | 4 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ortar, G | 1 |
| Cascio, MG | 1 |
| De Petrocellis, L | 1 |
| Morera, E | 2 |
| Rossi, F | 1 |
| Schiano-Moriello, A | 1 |
| Nalli, M | 1 |
| de Novellis, V | 1 |
| Woodward, DF | 1 |
| Maione, S | 1 |
| Di Marzo, V | 2 |
| Crivelaro do Nascimento, G | 1 |
| Ferrari, DP | 1 |
| Guimaraes, FS | 1 |
| Del Bel, EA | 1 |
| Bortolanza, M | 1 |
| Ferreira-Junior, NC | 1 |
| Rodrigues, FF | 1 |
| Morais, MI | 1 |
| Melo, ISF | 1 |
| Augusto, PSA | 1 |
| Dutra, MMGB | 1 |
| Costa, SOAM | 1 |
| Costa, FC | 1 |
| Goulart, FA | 1 |
| Braga, AV | 1 |
| Coelho, MM | 1 |
| Machado, RR | 1 |
| Godoi, MM | 1 |
| Junior, HZ | 1 |
| da Cunha, JM | 1 |
| Zanoveli, JM | 1 |
| Xu, X | 1 |
| Wu, K | 1 |
| Ma, X | 1 |
| Wang, W | 1 |
| Wang, H | 1 |
| Huang, M | 1 |
| Luo, L | 1 |
| Su, C | 1 |
| Yuan, T | 1 |
| Shi, H | 1 |
| Han, J | 1 |
| Wang, A | 1 |
| Xu, T | 1 |
| Wang, P | 1 |
| Zheng, T | 1 |
| Zhang, M | 1 |
| Xu, B | 1 |
| Zhang, R | 1 |
| Zhang, T | 1 |
| Zhao, W | 1 |
| Shi, X | 1 |
| Zhang, Q | 1 |
| Fang, Q | 2 |
| Rea, K | 2 |
| McGowan, F | 1 |
| Corcoran, L | 1 |
| Roche, M | 2 |
| Finn, DP | 2 |
| Giorno, TBS | 1 |
| Moreira, IGDS | 1 |
| Rezende, CM | 1 |
| Fernandes, PD | 1 |
| Dikmen, DY | 1 |
| Okcay, Y | 1 |
| Arslan, R | 1 |
| Bektas, N | 1 |
| Olango, WM | 1 |
| Harhen, B | 1 |
| Kerr, DM | 1 |
| Galligan, R | 1 |
| Fitzgerald, S | 1 |
| Moore, M | 1 |
| Elmas, P | 1 |
| Ulugol, A | 1 |
| Anderson, WB | 1 |
| Gould, MJ | 1 |
| Torres, RD | 1 |
| Mitchell, VA | 3 |
| Vaughan, CW | 3 |
| Petrenko, AB | 1 |
| Yamazaki, M | 1 |
| Sakimura, K | 1 |
| Kano, M | 1 |
| Baba, H | 1 |
| Malek, N | 1 |
| Mrugala, M | 1 |
| Makuch, W | 1 |
| Kolosowska, N | 1 |
| Przewlocka, B | 1 |
| Binkowski, M | 1 |
| Czaja, M | 1 |
| Starowicz, K | 1 |
| Mohammad-Pour Kargar, H | 1 |
| Azizi, H | 1 |
| Mirnajafi-Zadeh, J | 1 |
| Ali Reza, M | 1 |
| Semnanian, S | 1 |
| Carey, LM | 1 |
| Slivicki, RA | 1 |
| Leishman, E | 1 |
| Cornett, B | 1 |
| Mackie, K | 2 |
| Bradshaw, H | 1 |
| Hohmann, AG | 1 |
| Esmaeili, MH | 2 |
| Reisi, Z | 2 |
| Ezzatpanah, S | 2 |
| Haghparast, A | 3 |
| Sagar, DR | 1 |
| Kendall, DA | 2 |
| Chapman, V | 2 |
| Kawahara, H | 1 |
| Chen, L | 1 |
| Zhang, J | 1 |
| Li, F | 1 |
| Qiu, Y | 1 |
| Wang, L | 1 |
| Li, YH | 1 |
| Shi, J | 1 |
| Pan, HL | 1 |
| Li, M | 1 |
| Hasanein, P | 1 |
| Zhang, G | 1 |
| Chen, W | 1 |
| Lao, L | 1 |
| Marvizón, JC | 1 |
| Curto-Reyes, V | 1 |
| Llames, S | 1 |
| Hidalgo, A | 1 |
| Menéndez, L | 1 |
| Baamonde, A | 1 |
| Staniaszek, LE | 1 |
| Norris, LM | 1 |
| Barrett, DA | 1 |
| Ebrahimzadeh, M | 1 |
| Han, ZL | 1 |
| Li, N | 1 |
| Wang, ZL | 1 |
| He, N | 1 |
| Wang, R | 1 |
| Ho, YC | 1 |
| Lee, HJ | 1 |
| Tung, LW | 1 |
| Liao, YY | 1 |
| Fu, SY | 1 |
| Teng, SF | 1 |
| Liao, HT | 1 |
| Chiou, LC | 1 |
| Negrete, R | 1 |
| Hervera, A | 1 |
| Leánez, S | 1 |
| Martín-Campos, JM | 1 |
| Pol, O | 1 |
| Naderi, N | 1 |
| Majidi, M | 1 |
| Mousavi, Z | 1 |
| Khoramian Tusi, S | 1 |
| Mansouri, Z | 1 |
| Khodagholi, F | 1 |
| Tumati, S | 1 |
| Largent-Milnes, TM | 1 |
| Keresztes, A | 1 |
| Ren, J | 1 |
| Roeske, WR | 1 |
| Vanderah, TW | 1 |
| Varga, EV | 1 |
| Rezende, RM | 1 |
| Paiva-Lima, P | 1 |
| Dos Reis, WG | 1 |
| Camêlo, VM | 1 |
| Faraco, A | 1 |
| Bakhle, YS | 1 |
| Francischi, JN | 1 |
| Dogrul, A | 1 |
| Gul, H | 1 |
| Akar, A | 1 |
| Yildiz, O | 1 |
| Bilgin, F | 1 |
| Guzeldemir, E | 1 |
| Akerman, S | 1 |
| Kaube, H | 1 |
| Goadsby, PJ | 1 |
| Johanek, LM | 1 |
| Simone, DA | 1 |
| Antoniou, K | 1 |
| Galanopoulos, A | 1 |
| Vlachou, S | 1 |
| Kourouli, T | 1 |
| Nahmias, V | 1 |
| Thermos, K | 1 |
| Panagis, G | 1 |
| Daifoti, Z | 1 |
| Marselos, M | 1 |
| Papahatjis, D | 1 |
| Spyraki, C | 1 |
| Guindon, J | 2 |
| De Léan, A | 1 |
| Beaulieu, P | 2 |
| Liu, C | 1 |
| Walker, JM | 1 |
| Borsani, E | 1 |
| Labanca, M | 1 |
| Bianchi, R | 1 |
| Rodella, LF | 1 |
| Desroches, J | 1 |
| Dani, M | 1 |
| Greenwood, R | 1 |
| Jayamanne, A | 1 |
| Schuelert, N | 1 |
| McDougall, JJ | 1 |
| da Fonseca Pacheco, D | 1 |
| Klein, A | 1 |
| de Castro Perez, A | 1 |
| da Fonseca Pacheco, CM | 1 |
| de Francischi, JN | 1 |
| Duarte, ID | 1 |
| Mallet, C | 1 |
| Daulhac, L | 1 |
| Bonnefont, J | 1 |
| Ledent, C | 1 |
| Etienne, M | 1 |
| Chapuy, E | 1 |
| Libert, F | 1 |
| Eschalier, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet[NCT04195269] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-20 | Recruiting | ||
| Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms[NCT05142267] | 120 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | |||
| An Open-label, Single-dose, Pharmacokinetic Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Orthodontic Pain[NCT05844995] | Phase 1 | 30 participants (Anticipated) | Interventional | 2023-09-13 | Recruiting | ||
| A Full-Factorial, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose Efficacy and Safety Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen, and Naproxen Sodium in Postoperative Dental Pain[NCT05761574] | Phase 3 | 440 participants (Anticipated) | Interventional | 2023-05-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
44 other studies available for am 251 and Pain
| Article | Year |
|---|---|
New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Biphenyl Compounds; Brain; Calcium; Carbama | 2007 |
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox | 2020 |
Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Behavior, Animal; Carrageenan; | 2020 |
Mu-opioid and CB1 cannabinoid receptors of the dorsal periaqueductal gray interplay in the regulation of fear response, but not antinociception.
Topics: Analgesics, Opioid; Animals; Arachidonic Acids; Behavior, Animal; Cannabinoid Receptor Agonists; Can | 2020 |
mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress.
Topics: Animals; Cannabinoid Receptor Antagonists; Chronic Disease; Depressive Disorder, Major; Endocannabin | 2021 |
Antinociceptive effects of the endogenous cannabinoid peptide agonist VD-hemopressin(β) in mice.
Topics: Acetic Acid; Analgesics; Animals; Area Under Curve; Disease Models, Animal; Dose-Response Relationsh | 2018 |
The prefrontal cortical endocannabinoid system modulates fear-pain interactions in a subregion-specific manner.
Topics: Animals; Behavior, Animal; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Conditioning, Ps | 2019 |
New
Topics: Analgesics; Animals; Behavior, Animal; Capsaicin; Coffee; Disease Models, Animal; Female; Formaldehy | 2018 |
Cannabinoid system involves in the analgesic effect of protocatechuic acid.
Topics: Acetic Acid; Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxyb | 2019 |
Evidence for a role of GABAergic and glutamatergic signalling in the basolateral amygdala in endocannabinoid-mediated fear-conditioned analgesia in rats.
Topics: Amygdala; Analgesia; Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Conditioning, Psycho | 2013 |
Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazines; Cannabinoid Receptor Ago | 2013 |
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.
Topics: Amidohydrolases; Analgesics; Analysis of Variance; Animals; Arthritis, Experimental; Benzamides; Ben | 2014 |
Augmented tonic pain-related behavior in knockout mice lacking monoacylglycerol lipase, a major degrading enzyme for the endocannabinoid 2-arachidonoylglycerol.
Topics: Animals; Arachidonic Acids; Benzodioxoles; Cannabinoid Receptor Modulators; Endocannabinoids; Glycer | 2014 |
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Topics: Activating Transcription Factor 3; Amidohydrolases; Anilides; Animals; Arachidonic Acids; Benzamides | 2015 |
Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors.
Topics: Analgesics; Analysis of Variance; Animals; Benzoxazoles; Carrier Proteins; Dose-Response Relationshi | 2015 |
A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
Topics: Acrylamides; Amidohydrolases; Analgesia; Animals; Arachidonic Acid; Bridged Bicyclo Compounds, Heter | 2016 |
Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats.
Topics: Animals; Benzoxazoles; Carbachol; Disease Models, Animal; Hypothalamic Area, Lateral; Male; Microinj | 2016 |
Role of orexin-2 and CB1 receptors within the periaqueductal gray matter in lateral hypothalamic-induced antinociception in rats.
Topics: Animals; Carbachol; Disease Models, Animal; Dose-Response Relationship, Drug; Hypothalamic Area, Lat | 2017 |
Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain.
Topics: Amidohydrolases; Analgesia; Animals; Benzamides; Carbamates; Carrageenan; Disease Models, Animal; In | 2008 |
Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey.
Topics: Adamantane; Animals; Cannabinoid Receptor Modulators; Endocannabinoids; Excitatory Amino Acid Antago | 2009 |
Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats.
Topics: Animals; Arachidonic Acids; Chromatography, High Pressure Liquid; Electroacupuncture; Endocannabinoi | 2009 |
The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis.
Topics: Animals; Arachidonic Acids; Biological Transport; Camphanes; Cannabinoid Receptor Modulators; Choles | 2009 |
Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization.
Topics: Animals; Capsaicin; Electric Stimulation; GABA-B Receptor Antagonists; Injections, Spinal; Male; Mor | 2010 |
Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.
Topics: Analgesics; Animals; Bone Neoplasms; Camphanes; Cannabinoids; Cell Line, Tumor; Disease Models, Anim | 2010 |
Effects of COX-2 inhibition on spinal nociception: the role of endocannabinoids.
Topics: Animals; Cannabinoid Receptor Modulators; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response | 2010 |
Analgesic effects of cannabinoid receptor agonist WIN55,212-2 in the nucleus cuneiformis in animal models of acute and inflammatory pain in rats.
Topics: Analgesics; Analysis of Variance; Animals; Area Under Curve; Benzoxazines; Cannabinoid Receptor Agon | 2011 |
Effects of neuropeptide FF system on CB₁ and CB₂ receptors mediated antinociception in mice.
Topics: Analgesia; Analgesics; Animals; Benzoxazines; Indoles; Male; Mice; Morpholines; Naloxone; Naphthalen | 2012 |
Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition.
Topics: Analysis of Variance; Animals; Animals, Newborn; Arachidonic Acids; Benzoxazines; Benzoxazoles; Biph | 2011 |
The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids.
Topics: Analgesics; Analgesics, Opioid; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagon | 2011 |
The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats.
Topics: Amides; Animals; Drug Interactions; Endocannabinoids; Ethanolamines; Injections, Spinal; Interleukin | 2012 |
Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.
Topics: Analgesics; Analgesics, Opioid; Animals; Cannabinoids; Hyperalgesia; Indoles; Inflammation; Interleu | 2012 |
Endogenous opioid and cannabinoid mechanisms are involved in the analgesic effects of celecoxib in the central nervous system.
Topics: Analgesics; Animals; Carrageenan; Celecoxib; Central Nervous System; Cyclooxygenase 2; Cyclooxygenas | 2012 |
Topical cannabinoid antinociception: synergy with spinal sites.
Topics: Administration, Topical; Analgesics; Animals; Benzoxazines; Cannabinoids; Dose-Response Relationship | 2003 |
Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception.
Topics: Animals; Arachidonic Acids; Blood Pressure; Calcitonin Gene-Related Peptide; Capsaicin; Electric Sti | 2004 |
Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Topics: Animals; Benzoxazines; Burns; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disea | 2004 |
Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3.
Topics: Animals; Behavior, Animal; Binding, Competitive; Cannabinoids; Catalepsy; Cell Membrane; Cerebral Co | 2005 |
Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain.
Topics: Acute Disease; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic A | 2006 |
Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Topics: Analgesics; Animals; Behavior, Animal; Benzoxazines; Camphanes; Cannabinoid Receptor Agonists; Canna | 2006 |
AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain.
Topics: Animals; Arachidonic Acids; Capsaicin; Endocannabinoids; Immunohistochemistry; Indoles; Inflammation | 2007 |
Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Hyperalgesia; Indoles; Male; Morpholines; Naphthale | 2007 |
Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
Topics: Analgesics; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Carrier Proteins; Disease M | 2007 |
Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees.
Topics: Afferent Pathways; Anilides; Animals; Arachidonic Acids; Cinnamates; Knee Joint; Male; Nociceptors; | 2008 |
The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
Topics: Amidohydrolases; Analgesics, Opioid; Animals; Arachidonic Acids; Benzamides; Benzomorphans; Cannabin | 2008 |
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.
Topics: Acetaminophen; Analgesia; Animals; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug | 2008 |
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.
Topics: Acetaminophen; Analgesia; Animals; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug | 2008 |
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.
Topics: Acetaminophen; Analgesia; Animals; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug | 2008 |
Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia.
Topics: Acetaminophen; Analgesia; Animals; Cannabinoid Receptor Modulators; Dose-Response Relationship, Drug | 2008 |